TY - JOUR
T1 - Personalized medication response prediction for attention-deficit hyperactivity disorder
T2 - Learning in the model space vs. learning in the data space
AU - Wong, Hin K.
AU - Tiffin, Paul A.
AU - Chappell, Michael J.
AU - Nichols, Thomas E.
AU - Welsh, Patrick R.
AU - Doyle, Orla M.
AU - Lopez-Kolkovska, Boryana C.
AU - Inglis, Sarah K.
AU - Coghill, David
AU - Shen, Yuan
AU - Tiño, Peter
N1 - Support from the UK Engineering and Physical Sciences Research Council (EPSRC), grant number EP/L000296/1. The ADDUCE project from which this piece of research borrowed clinical data is Frontiers in Physiology | www.frontiersin.org 19 April 2017 | Volume 8 | Article 199 Wong et al. Personalized Response Prediction for ADHD funded by the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement number 260576.
PY - 2017/4/11
Y1 - 2017/4/11
N2 - Attention-Deficit Hyperactive Disorder (ADHD) is one of the most common mental health disorders amongst school-aged children with an estimated prevalence of 5% in the global population (American Psychiatric Association, 2013). Stimulants, particularly methylphenidate (MPH), are the first-line option in the treatment of ADHD (Reeves and Schweitzer, 2004; Dopheide and Pliszka, 2009) and are prescribed to an increasing number of children and adolescents in the US and the UK every year (Safer et al., 1996; McCarthy et al., 2009), though recent studies suggest that this is tailing off, e.g., Holden et al. (2013). Around 70% of children demonstrate a clinically significant treatment response to stimulant medication (Spencer et al., 1996; Schachter et al., 2001; Swanson et al., 2001; Barbaresi et al., 2006). However, it is unclear which patient characteristics may moderate treatment effectiveness. As such, most existing research has focused on investigating univariate or multivariate correlations between a set of patient characteristics and the treatment outcome, with respect to dosage of one or several types of medication. The results of such studies are often contradictory and inconclusive due to a combination of small sample sizes, low-quality data, or a lack of available information on covariates. In this paper, feature extraction techniques such as latent trait analysis were applied to reduce the dimension of on a large dataset of patient characteristics, including the responses to symptom-based questionnaires, developmental health factors, demographic variables such as age and gender, and socioeconomic factors such as parental income. We introduce a Bayesian modeling approach in a "learning in the model space" framework that combines existing knowledge in the literature on factors that may potentially affect treatment response, with constraints imposed by a treatment response model. The model is personalized such that the variability among subjects is accounted for by a set of subject-specific parameters. For remission classification, this approach compares favorably with conventional methods such as support vector machines and mixed effect models on a range of performance measures. For instance, the proposed approach achieved an area under receiver operator characteristic curve of 82-84%, compared to 75-77% obtained from conventional regression or machine learning ("learning in the data space") methods.
AB - Attention-Deficit Hyperactive Disorder (ADHD) is one of the most common mental health disorders amongst school-aged children with an estimated prevalence of 5% in the global population (American Psychiatric Association, 2013). Stimulants, particularly methylphenidate (MPH), are the first-line option in the treatment of ADHD (Reeves and Schweitzer, 2004; Dopheide and Pliszka, 2009) and are prescribed to an increasing number of children and adolescents in the US and the UK every year (Safer et al., 1996; McCarthy et al., 2009), though recent studies suggest that this is tailing off, e.g., Holden et al. (2013). Around 70% of children demonstrate a clinically significant treatment response to stimulant medication (Spencer et al., 1996; Schachter et al., 2001; Swanson et al., 2001; Barbaresi et al., 2006). However, it is unclear which patient characteristics may moderate treatment effectiveness. As such, most existing research has focused on investigating univariate or multivariate correlations between a set of patient characteristics and the treatment outcome, with respect to dosage of one or several types of medication. The results of such studies are often contradictory and inconclusive due to a combination of small sample sizes, low-quality data, or a lack of available information on covariates. In this paper, feature extraction techniques such as latent trait analysis were applied to reduce the dimension of on a large dataset of patient characteristics, including the responses to symptom-based questionnaires, developmental health factors, demographic variables such as age and gender, and socioeconomic factors such as parental income. We introduce a Bayesian modeling approach in a "learning in the model space" framework that combines existing knowledge in the literature on factors that may potentially affect treatment response, with constraints imposed by a treatment response model. The model is personalized such that the variability among subjects is accounted for by a set of subject-specific parameters. For remission classification, this approach compares favorably with conventional methods such as support vector machines and mixed effect models on a range of performance measures. For instance, the proposed approach achieved an area under receiver operator characteristic curve of 82-84%, compared to 75-77% obtained from conventional regression or machine learning ("learning in the data space") methods.
KW - Attention-deficit hyperactivity disorder
KW - Bayesian inference
KW - Machine learning
KW - Methylphenidate
KW - Mixed effects model
KW - Personalized medicine
KW - Prognosis
KW - Treatment response
UR - http://www.scopus.com/inward/record.url?scp=85018430971&partnerID=8YFLogxK
U2 - 10.3389/fphys.2017.00199
DO - 10.3389/fphys.2017.00199
M3 - Article
C2 - 28443027
AN - SCOPUS:85018430971
SN - 1664-042X
VL - 8
SP - 1
EP - 21
JO - Frontiers in Physiology
JF - Frontiers in Physiology
IS - APR
M1 - 199
ER -